tbuckley/cabot-search huggingface dataset:
SAT0387 Anti Tnf Treatment of Reactive Arthritis. A Monocentric Experience: Table 1
Authors: A. Brinster, X. Guillot, C. Prati, D. Wendling
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Reactive arthritis is still a matter of interest and a current problem, since its treatment is not standardized, with the possibility of a chronic evolution. Nevertheless, anti TNF agents may be of interest, as illustrated by small multicentric series. <h3>Objectives</h3> To evaluate efficacy and safety of anti TNF agents in the treatment of patients with reactive arthritis followed in a single center. <h3>Methods</h3> We analyzed retrospectively the data of patients with reactive arthritis, according to proposed criteria treated with TNF blockers, from July 2007 to December 2013 in an University Hospital in France. <h3>Results</h3> Over this period, 31 cases of Reactive arthritis were followed in our department, of whom 15 (48%) received at least one dose of anti TNF. They are in majority male (n=13), mean age 35 years, 66% HLA-B27 positive. Evidence of infection was found in 9/15 patients (4 Chlamydia). After failure of NSAIDs, steroids and conventional DMARDs, anti TNF agents were introduced with a median delay of 116 days after onset of rheumatic symptoms: etanercept (ETN) 9 cases, infliximab (IFX) and adalimumab (ADA) (3 cases each) (Table). The clinical improvement was rapid, all the patients developed a clinical response to anti TNF therapy which could be stopped in 5 cases: 3 IFX after a mean of 4.6 infusions, 2 ETN after 4 and 10 months. Eight patients developed chronic spondyloarthritis, and one psoriatic arthritis, with a mean follow-up of 4.8 years, and requiring anti TNF continuation. The last patient was lost in follow-up. The treatment was well tolerated, with a mean exposition duration of 34 months by patient, neither serious infection nor reactivation of the triggering infection was recorded. Compared to the patients with reactive arthritis not treated with anti TNF over the same period, we found no differences regarding clinical data (age, arthritis distribution, type of initial infection), biologic data (CRP, HLA-B27 positivity, evidence of infectious agent). Dactylitis were more frequent (although not significant) in patients treated with anti TNF agents (40% vs 20%). In the same way, there were no differences between the patients who could stop anti TNF after several months, due to remission, and those for whom continuation was necessary, except a shorter median delay of initiation of the TNF blocker: 44 days versus 173 days respectively. <h3>Conclusions</h3> Anti TNF therapy for reactive arthritis seems to be associated with symptomatic efficacy and good tolerance with the possibility, in one third of the cases of short lasting treatment leading to remission, which seems associated to the precocity of anti TNF initiation, suggesting a kind of window of opportunity in this subset of spondyloarthritis. However, the impact of this treatment upon the outcome of the disease needs to be further evaluated. <h3>Disclosure of Interest</h3> None declared
AB0951 Ultrasonographic Differentiation between PSA and RA Based on Finger Flexor Tendon Pulley Entheseal Complex: Table 1
Authors: I. Tinazzi, P. Macchioni, A. Marchetta, M. Catanoso, D. Mc Gonagle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Both RA and PsA are associated with hand involvement including synovitis and tenosynovitis. Differentiation between RA and PsA can sometimes be impossible using existing serological, genetic and imaging biomarkers. At the micro anatomical level PsA is strongly linked to disease localisation to entheses and other sites of high mechanical stressing. Recently high resolution MRI has shown prominent abnormalities at the mini-entheses of the flexor tendon pulleys may be common (1). <h3>Objectives</h3> This study tested the hypothesis that that mini-entheses disease of the hand including the A1,3, and 5 pulleys and flexor tendon insertion could be used to differentiate between RA and PsA. <h3>Methods</h3> 46 cases of seropositive RA and 37 PsA patients were consecutively recruted. Cases were matched for disease duration, age and BMI with the majority being under therapy with conventional DMARDs (table1). Patients underwent completely rheumatological examination (AM, MC) and CRP and ESR determination. US examination was done with ESAOTE MyLabClass equiped with 18–6 linear probe. The 2nd to 4th dominant finger were scanned both on the dorsal and palmar surface. The sonograraphers (IT, PM) were blinded to the clinical details. The following changes were recorded as present (1) or absent (0): tendon flexor tenosynovitis, flexor pseudotensynovitis (peritendinous oedema), bone formation and the DIP flexor tendon insertion enthesophyte or calcifcations. A1, 3 and 5 pulley tendon thickness was measured at the level of maximal thickness in longitudinal or transverse way. The ecogenicity of the pulley was recorded as normal (if anecogen) or abnormal (no complete anecogenicity). <h3>Results</h3> Flexor tenosynovitis was evident in 25/108 digits in PsA versus 8/135 in RA (p&lt;0.001). Peritendinous oedema was evident in 23/108 PsA digit compared to only 8/135 RA digit (p&lt;0.001) despite the fact that the magnitude of tenosynovitis was the same in RA and PsA. The A1, A3 and A5 pulleys were <i>not</i> significantly thicker in PsA compared to RA. Flexor tendon enthesopathy as determined by intra tendinous new bone was evident in 78/108 PsA cases, 21/135 RA and 2/30 health control (p&lt;0.001 for both comparisons. <h3>Conclusions</h3> This study suggests that PsA cases have a much higher burden of abnormalities in the min-entheses of the hand flexor tendons. With the improving resolution and capabilities of MKUS these findings may be relevant for defining the phenotype of joint swelling as RA (synovial centric) or SpA (entheseal like). <h3>References</h3> Tan AL. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis.Ann Rheum Dis. 2015 Jan;74(1):185–9. <h3>Disclosure of Interest</h3> None declared
Abstract 1746: Discovery and evaluation of a small molecule KIFC1 inhibitor for breast cancer treatment
Authors: Wei Zhang, Ling Zhai, Wenyan Lu, Yimin Wang, Vandana V. Gupta, Indira Padmalayam, Robert J. Bostwick, Lucile White, Ross Larry, Joseph Maddry, Sam Ananthan, Mark Suto, Bo Xu, Rongbao Li, Yonghe Li
Journal: Cancer Research (2015)

Abstract Historically, drugs used in the treatment of certain cancers may cause damage to healthy cells while affecting cancer cells. Therefore, finding compounds that are specific toward cancer cells only is still a high priority in the search for new therapies. In contrast with normal cells, most cancer cells contain multiple centrosomes which are associated with genome instability and tumorigenesis. Cancer cells can avoid multipolar mitosis which can cause cell death by clustering the extra centrosomes into two spindle poles, thereby enabling bipolar division. Kinesin-like protein KIFC1 plays a critical role in centrosome clustering in cancer cells, but is not essential for normal cell survival. Therefore, targeting KIFC1 may give some insight into how a novel therapy can selectively target only cancer cells. Here, we report that KIFC1 up-regulation is a frequent event in human breast cancer and that KIFC1 is highly expressed in all 8 tested human breast cancer cell lines, but is absent in normal human mammary epithelial cells and weakly expressed in 2 human lung fibroblast lines. We also found that depletion of KIFC1 in breast cancer cells induced cell death. From a high throughput screen of 30,000 compounds, we identified a small molecule KIFC1 inhibitor, SRH06, which has an enzymatic IC50 value of 6.5 μM versus KIFC1 and binds directly to KIFC1 without interacting with the microtubule. Results from our computer modeling studies suggested that SRH06 binds to a novel allosteric site on KIFC1 that appears suitable for the development of selective KIFC1 inhibitors. Importantly, SRH06 prevented bipolar clustering of extra-centrosomes in breast cancer cells and significantly reduced colony formation and cell viability, but was less toxic to normal LL47 fibroblasts. Therefore, SRH06 provides a very valuable tool to study the biological function of KIFC1 and serves as a potential lead for the development of a novel therapeutic agent for the treatment of breast cancer. Citation Format: Wei Zhang, Ling Zhai, Wenyan Lu, Yimin Wang, Vandana V. Gupta, Indira Padmalayam, Robert J. Bostwick, Lucile White, Ross Larry, Joseph Maddry, Sam Ananthan, Mark Suto, Bo Xu, Rongbao Li, Yonghe Li. Discovery and evaluation of a small molecule KIFC1 inhibitor for breast cancer treatment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1746. doi:10.1158/1538-7445.AM2015-1746
Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.
Authors: Silvia Zibellini, Daniela Capello, Francesco Forconi, Sara Rattotti, Silvia Franceschetti, Elisa Sozzi, Emanuele Cencini, Roberto Marasca, Luca Baldini, Alessandra Tucci, Davide Rossi, Francesco Bertoni, Francesco Passamonti, Ester Orlandi, Marzia Varettoni, Michele Merli, Virginia Ferretti, Cristiana Pascutto, Marco Paulli, Gianluca Gaidano, Luca Arcaini
Journal: Blood (2009)
Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
Authors: Kenneth A. Ault, Delvyn Caedren Case, Marjorie A. Boyd, Thomas J. Ervin, Frederick Aronson, Kurt S. Ebrahim, Jacquelyn A. Hedlund
Journal: Blood (2006)
Applicability of FLT3-Length Mutations in Exon 14 as a Follow up Marker in AML: An Experience of 148 Cases and 517 Follow up Samples Using Conventional and Real Time PCR.
Authors: Susanne Schnittger, Wolfgang Kern, Gudrun Mellert, Wolfgang Hiddemann, Claudia Schoch, Torsten Haferlach
Journal: Blood (2004)
The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.
Authors: Nicholas C.P. Cross, Peter Campbell, Philip A Beer, Susanne Schnittger, Alessandro M. Vannucchi, Katerina Zoi, Melanie Percy, Mary Frances McMullin, Linda Scott, Richard T. Silver, David Oscier, Claire Harrison, Anthony R. Green, Andrew Chase
Journal: Blood (2009)
Expression Levels of CD11b, CD18, CD32, CD62L (L-Selectin) and CD62P (P-Selectin) and Its Role in Sickle Cell Anemia Inflammatory State
Authors: Bruno Antônio Veloso Cerqueira, Wendell Vilas Boas, Magda Oliveira Seixas, Elder Trindade Damasceno, Cyntia Cajado Souza, Mitermayer Galvão Reis, Marilda Souza Goncalves
Journal: Blood (2008)
Inhibition of the NPM-ALK Fusion Tyrosine Kinase in Hematopoietic Neoplasia by the Small Molecule Tyrosine Kinase Antagonist TAE684.
Authors: David W. Sternberg, Arghya Ray, Benjamin H. Lee, Jennifer Adelsperger, Nicole Duclos, Elizabeth McDowell, Naznin Haq, Patricia Imbach, Osamu Ohmori, Toshiyuki Honda, Markus Warmuth, Doriano Fabbro, James D. Griffin, Johannes Roesel
Journal: Blood (2006)
Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation
Authors: Robert Chen, Joycelynne Palmer, Leona Holmberg, Jessica Alluin, Pritsana Chomchan, Leslie L. Popplewell, Tanya Siddiqi, Sandra H. Thomas, Kathryn Irenze, Auayporn P. Nademanee, Ricardo Spielberger, John J Rossi, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman
Journal: Blood (2015)
SAT0098 Risk of Hospitalization for Serious Bacterial Infections in Patients with Rheumatoid Arthritis Treated with Biologics. Analysis from The Record Study of The Italian Society for Rheumatology
Authors: A. Bortoluzzi, G. Sakellariou, G. Carrara, M. Govoni, C.A. Scirè
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biological disease modifying antirheumatic drugs (bDMARDs) are widely used in treating rheumatoid arthritis (RA). There are concerns regarding the risk of serious infections related to these treatments, and scarce information on the impact of co-treatments. <h3>Objectives</h3> To define the risk of serious infections in patients receiving bDMARDs, evaluating the effect of specific biologic agents and co-treatments in a large population-based sample of RA deriving from the administrative health database of the Lombardy region in Italy. <h3>Methods</h3> Data were extracted from health databases of the Lombardy Region in the period between 1/1/2004 and 31/12/2013. Patients with RA, identified through a rheumatologist certified diagnosis (exemption code 006.714.0) and treated with bDMARDs (abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab) were included. Hospitalizations for bacterial infections were evaluated by the hospital discharge forms in the period of exposure to each biologic drug with the following diagnosis ICD9CM: 049.* or 320.*, 054.3 or 323.*, 681.*682.*, 421.*, 481.*482.*, 590.*, 711.*, 730.0*730.2*, 038.* or 790.7. The association between biologic drugs exposure and hospitalization for bacterial infections was assessed by survival models for competing risks, with time-dependent covariates. Results were presented as hazard ratios (HR) and 95% confidence intervals (CI), crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson comorbidity index, concomitant use of methotrexate, leflunomide, corticosteroids, NSAIDs, number of previous biologics and previous infections). <h3>Results</h3> 4656 RA patients who had at least one bDMARD prescription for a total of 7601 exposures were included. 3603 were women (77.4%) with a mean age at first bDMARD exposure of 55.7 years (12.7 ± SD) and with a modal disease duration over 5 years. The factors associated with hospitalization with a definite bacterial infection are shown in figure. Considering etanercept as reference, the adjusted HR for infection was equal to 0.29 (95% IC 0.10 - 0.82) for abatacept, while it was not significantly different compared to other bDMARDs. <h3>Conclusions</h3> Treatment with bDMARDs was not associated with an increase in hospitalized infection. The risk was lower with abatacept that confirmed to have a better safety profile. <h3>Disclosure of Interest</h3> None declared
Factors Influencing Relapse after Allogeneic Hematopoietic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS.
Authors: Haifa K. Al-Ali, Claudia Nehring, Rainer Krahl, Cornelia Becker, Sabine Leiblein, Jeanett Edelmann, Wolfram Poenisch, Thoralf Lange, Dietger Niederwieser
Journal: Blood (2007)
Kinetics of Serum Macrophage Migration Inhibitory Factor (MIF) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Allogeneic Stem Cell Transplantation.
Authors: Tomomi Toubai, Junji Tanaka, Shuichi Ota, Junichi Sugita, Naoko Kato, Keiichi Kondo, Noriaki Iwao, Masahiro Asaka, Masahiro Imamura
Journal: Blood (2005)
Функціональна диспепсія у світлі PимскИх критеріїв IV
Authors: S.M. Tkach
Journal: GASTROENTEROLOGY (2016)

Статтю присвячено проблемі функціональної дис­пепсії. Детально описана патофiзiологiя, наведені діагностичні критерії цієї патології, розглядаються аспекти лікування пацієнтів iз функціональною диспепсією. Препаратами першої лінії терапії функціональної диспепсії є прокiнетики і інгібітори протонної помпи. У статті приділено увагу комбінованому препарату, що містить домперидон (прокінетик) і омепразол (інгібітор протонної помпи), — Омез ДСР.
The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee
Authors: M.J. Ellington, O. Ekelund, F.M. Aarestrup, R. Canton, M. Doumith, C. Giske, H. Grundman, H. Hasman, M.T.G. Holden, K.L. Hopkins, J. Iredell, G. Kahlmeter, C.U. Köser, A. MacGowan, D. Mevius, M. Mulvey, T. Naas, T. Peto, J.-M. Rolain, Ø. Samuelsen, N. Woodford
Journal: Clinical Microbiology and Infection (2016)
Multiple Mapping of Peptide Sequences Recognized by Various Monoclonal Anti-ADAMTS13 Antibodies with Functional or Nonfunctional Effects On the Catalytic Activity.
Authors: Terumichi Nakagawa, Takanori Moriki, Yusuke Yamaguchi, Atsuko Igari, Kenji Soejima, Masanori Matsumoto, Yoshihiro Fujimura, Mitsuru Murata
Journal: Blood (2009)
AB0789 BMD Change around Prosthesis after Uncemented Total Hip Arthroplasty in RA Patients: 15-Year Follow Up
Authors: M. Makarov, S. Makarov, E. Byalik, A. Logunov, G. Vardikova, M. Lipina, V. Kolomatsky, V. Pavlov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In previous studies we noted that maximum bone loss around total hip prosthesis occurs in first six months after surgery. After six months bone loss becomes slower and in some cases BMD even can increase. <h3>Objectives</h3> To study the 15-year follow up changes of BMD in patients with RA. <h3>Methods</h3> 282 RA patients were examined at the baseline. At the end of investigation we analyzed 43 patients. DEXA was used for BMD assessment around stem (7 ROIs) and cup (3 ROIs) of prosthesis. First examination was conducted 2 weeks after the operation and repeated at 3, 5, 10 and 15 year after surgery. <h3>Results</h3> 3 years after decrease of BMD was -5,8% and -4,9% around stem and cup respectively (p&lt;0,01). By 5 and 10 year the bone loss was not significant (-6,1% and -5,5%; -7,1% and -6,3% around stem and cup respectively). 15 years after surgery we observed significant increase of bone loss (-18,9% and -22,7% around stem and cup respectively (p&lt;0,01)) <h3>Conclusions</h3> These data supports our opinion of stress remodeling of bone around hip prosthesis. This phenomenon doesn9t stop after 1 year but keep on even 15 years after surgery. This means that all RA patients after THA need to use medication to normalize bone remodeling <h3>Disclosure of Interest</h3> None declared
Inhibition of Sorbitol Dehydrogenase Increases Platelets Adhesion in Animals Mice with Fidarestat
Authors: Mariane Cristina Flores-Nascimento, Kiara Cristina Senger Zapponi, Camila Mendes, Regiane Ferreira, Lucia Helena Siqueira, Thais Arouca Fornari, Fernanda Loureiro de Andrade Orsi, Bruna M Mazetto, Joyce M Annichino-Bizzacchi
Journal: Blood (2014)
Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis
Authors: Aaron C. Logan, Alex F. Herrera, Christine E. Ryan, Andrew R. Rezvani, Katherine A. Kong, Malek Faham, Gheath Alatrash, Jeffrey J. Molldrem, Rachel L. Sargent, Edwin P. Alyea, Vincent T. Ho, Jennifer R. Brown, Jerome Ritz, David B. Miklos
Journal: Blood (2015)
SAT0302 Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression
Authors: A. Berti, A. Baragetti, M. Magnoni, K. Garlaschelli, L. Grigore, M. Berteotti, I. Scotti, E. Bozzolo, G.A. Ramirez, A.A. Manfredi, E. Ammirati, A.L. Catapano, G.D. Norata
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A relationship between systemic inflammation and increased cardiovascular risk is often postulated. Simple and affordable clinical predictors of increased cardiovascular risk in patients with autoimmune disease, however, are not yet available in the clinical practice. <h3>Objectives</h3> To address the role of clinical, serological markers of disease activity, and of classical cardiovascular risk factors (CVRF) in predicting the carotid intima-media thickness (c-IMT) progression at 5 years (Δc-IMT) in patients with the prototypic autoimmune disease systemic lupus erythematosus (SLE). <h3>Methods</h3> Clinical and biochemical data including SLEDAI were collected at baseline and at five years of follow up from 50 patients with SLE and 50 age- and gender-matched healthy controls. C-IMT was also measured at baseline and at 5 years to evaluate progression. <h3>Results</h3> A higher SLEDAI score at baseline correlated with a faster Δc-IMT (0.007 (0.006) mm/year vs 0.003 (0.001) mm/year when compared to controls, P=0.026), irrespectively of the presence of CVRF and of the serological profile. Patients with higher SLEDAI score at baseline also experienced disease flares more frequently (p=0.037) than those with milder disease at baseline. Patients with a higher disease activity during follow up had also a faster Δc-IMT when compared to those with a persistently low disease activity (0.008 (0.004) mm/year vs -0.006 (0.004) mm/year, P=0.021). Elevated LDL-C levels were the only CVRF associated with disease flare-up; this might a consequence of the aggressive immunosuppressant therapy in those patients. <h3>Conclusions</h3> Patient with SLE show an increased cardiovascular risk as estimated by the c-IMT. Disease activity and in particular disease flares accelerate the progression of the vascular damage. <h3>Disclosure of Interest</h3> None declared
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Authors: Jinghe Huang, Byong H. Kang, Elise Ishida, Tongqing Zhou, Trevor Griesman, Zizhang Sheng, Fan Wu, Nicole A. Doria-Rose, Baoshan Zhang, Krisha McKee, Sijy O’Dell, Gwo-Yu Chuang, Aliaksandr Druz, Ivelin S. Georgiev, Chaim A. Schramm, Anqi Zheng, M. Gordon Joyce, Mangaiarkarasi Asokan, Amy Ransier, Sam Darko, Stephen A. Migueles, Robert T. Bailer, Mark K. Louder, S. Munir Alam, Robert Parks, Garnett Kelsoe, Tarra Von Holle, Barton F. Haynes, Daniel C. Douek, Vanessa Hirsch, Michael S. Seaman, Lawrence Shapiro, John R. Mascola, Peter D. Kwong, Mark Connors
Journal: Immunity (2016)
Outcomes of a Prospective Phase II Study of Reduced-Intensity Stem Cell Transplantation for Acute Myeloid Leukemia with t(8;21)- In Comparison with Autologous and Myeloablative Allogeneic Stem Cell Transplantation.
Authors: Ki-Seong Eom, Hee-Je Kim, Byung-Sik Cho, Seung-Eun Lee, Seung-Ah Yahng, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Chong-Won Park, Woo-Sung Min
Journal: Blood (2010)
Transcriptional Antagonism Between the Cooperative Oncogenes TLX1 and NOTCH1 in T-Cell Acute Lymphoblastic Leukemia
Authors: Kaat Durinck, Wouter Vanloocke, Joni Van der Meulen, Inge van de Walle, Pieter Rondou, Charles De Bock, Bruno Verhasselt, Bruce Graham Poppe, Jan Cools, Jean Soulier, Tom Taghon, Frank Speleman, Pieter Van Vlierberghe
Journal: Blood (2014)
Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.
Authors: Danielle Shafer, Hossein Borghaei, Michael Millenson, Nicos Nicolaou, Tahseen I. Al-Saleem, Nick C. Leasure, Kris Padavic, Mitchell R. Smith, Russell J. Schilder
Journal: Blood (2005)